Relationship between oxidative stress and clinical pregnancy in assisted reproductive technology treatment cycles.

PURPOSE: To examine the relationship between serum total oxidant (TOS) and antioxidant (TAS) levels and clinical pregnancy in assisted reproductive technology (ART) cycles.
METHODS: Prior to and after oocyte pick-up (OPU) and embryo transfer (ET), blood samples were collected from gynecologically normal females (n = 70) who were enrolled for ART solely due to male factor infertility. TAS, TOS levels and oxidative stress indexes (OSI: TOS/TAS) in four phases of treatment cycle (pre and post OPU and ET) between clinically pregnant and non-pregnant patients were compared. Critical cut-off values of significantly different TAS, TOS levels and OSIes for clinical pregnancy were established.
RESULTS: The TAS levels in patients with clinical pregnancy were significantly higher in all of the four phases of the cycle. Post-OPU and pre-ET TOS levels were significantly higher in clinically pregnant patients. According to OSIes; only the pre-OPU OSI was significantly lower in clinically pregnant patients compared with non-pregnant ones. Moreover, the highest area under the ROC curve (AUC) from the seven different significant measurements [1) pre-OPU OSI, 2) pre-OPU TAS, 3) post-OPU TAS, 4) pre-ET TAS, 5) post-ET TAS, 6) post-OPU TOS, 7) pre-ET TOS] was related to pre-OPU OSI.
CONCLUSIONS: In ART cycles, women with a higher total antioxidant status prior to and after OPU and prior to and after ET have an increased probability of clinical pregnancy. Additionally; OSI before OPU was one of the most important determinants for clinical pregnancy, so the oxidant and antioxidant balance is as important as the antioxidant concentration alone.

Introduction

Considering recent studies, it is believed that the oxidative stress balance plays a significant role in the normal functioning of the female reproductive system as well as many other systems. The development of imbalance between oxidants and antioxidants in the female reproductive system results in oxidative stress (OS) [1]. It was shown that reactive oxygen species (ROS), which are markers of oxidative stress, in follicular fluid, are important factors in the development and quality of embryos [7]. In another group of studies, the ROS level in embryo culture medium was reported to negatively affect embryo cleavage and could even help to predict clinical pregnancies [5, 6]. Considering these findings, the ROS level observed as an embryonic metabolic marker in embryo culture medium can be used as one of the criteria for embryo selection, and more clinical pregnancies can be attained by single ET, which can be performed based on this approach [12].

In contrast, oxidative stress markers in peritoneal fluid were higher in unexplained infertile couples, which constitutes one of the major patient groups among infertile individuals [2]. However, in patients with endometriosis, in which the worst results are expected in ART treatment, the antioxidant levels were found to be lower [17]. Today, there is no debate that especially in infertile couples, oxidative stress has an impact on many characteristics, including follicular fluid, embryo culture medium, the endometrial implantation phase and the continuity of the corpus luteum [2]. However, most of the studies on the effect of oxidative stress on female infertility were animal or in vitro studies, and their results were contradictory [3].

Our aim in this study was to examine the relationship between serum total oxidant and antioxidant levels and clinical pregnancy and evaluate this relationship in terms of predicting clinical pregnancy in 70 couples who were admitted to ART treatment solely because of male factor infertility; in these couples, the women were completely normal from a fertility perspective. To our knowledge, no study in the literature has examined the correlation between blood total oxidant and antioxidant levels and clinical pregnancy in women with normal characteristics who were admitted to ART treatment solely due to male factor infertility.

Methods

This prospective cohort study was conducted between September 2011 and July 2012 at Eskisehir Osmangazi University, Medical Faculty-Center for Reproductive Health, and approved by the Ethical Review Board of the hospital. A total of 70 patients attending the IVF unit of the center for ICSI cycles were recruited according to the following criteria: i) absence of any apparent abnormality of the reproductive system, as revealed by their medical history, clinical examinations and common hormonal tests; ii) absence of any metabolic or endocrine system-associated diseases, such as hyperprolactinemia, thyroid dysfunction, or polycystic ovary syndrome as defined by the Rotterdam criteria; iii) absence of any surgical history regarding the reproductive system; iv) normal ovulatory cycle, with cycle lengths of between 25 and 35 days; v) age of women between 27 and 36 years; vi) expected normal responders, as day 3 basal ultrasonography and a hormone profile revealed the following among all the women: FSH <10 mIU/ml, estradiol <40 pg/ml and antral follicle count (AFC) >6; vii) absence of any smoking history in women; and viii) indication for assisted reproductive technology (ART) treatment as exclusively advanced male factor infertility (severe oligoasthenoteratospermia [severe oligospermia (<5 million sperm/ml), asthenospermia (<5 % progressive motility), or teratospermia (<4 % normal forms by strict criteria)] according to WHO criteria [21], ix) only couples with sperm can be obtained from ejaculation, so we totally excluded couples who had surgical sperm extraction or aspiration indication due to azoospermia. Patients gave their written informed consent and did not receive any monetary compensation for participating in the study. Only the first cycle of each patient was included in the study.

All women received the long gonadotropin-releasing hormone agonist protocol for controlled ovarian hyper stimulation (COH). To achieve pituitary desensitization, leuprolide acetate (Lucrin®; Abbott Laboratories, Istanbul, Turkey) was initiated on day 21 of the previous cycle at a dose of 10 U, and it was decreased to 5 U on days 2–3 of menstrual bleeding. As soon as menstruation began, ovarian stimulation was initiated with 150–250 U/day rec-FSH (Puregon®; MSD, Istanbul, Turkey). Recombinant hCG (Ovitrelle®, Serono, Istanbul, Turkey) was applied when ≥3 follicles reached ≥17 mm, and oocyte pick-up (OPU) was performed under sedation at the 36th hour following hCG. On oocyte retrieval day, sperm was collected into a sterile plastic container from males who refrained from ejaculation for 3–5 days prior to the procedure. Following sperm preparation with a density gradient method, the ICSI procedure was performed using sperm that was selected by embryologists 2–3 h after OPU. A fertilization (two pronuclei) check was performed on embryos that were followed in cleavage stage medium (G1.3; Vitrolife®, Kungsbacka, Sweden) at 16–18 h, and embryos were observed until the 3rd day after OPU. After embryologists performed a control on the 3rd day, one embryo that was grade I according to the ESHRE consensus [4] was selected for transfer. All transfers were performed under ultrasonography, and a soft transfer catheter was used (Wallace Embryo Replacement Catheter, Ref. 1816N; Smiths Medical International Limited, Kent, UK).

Serum hCG levels were measured in all patients on the 14th day following ET. Patients with >50 IU/L hCG level were evaluated as pregnancy positive. In patients with a positive initial hCG measurement, a twofold increase was evaluated after 48 h. Transvaginal ultrasonography was performed 3 weeks later in patients who showed an increase, and those with a fetal structure and fetal cardiac activity were considered as clinical pregnancy positive.

Prior to and after oocyte retrieval and prior to and after transfer, 3–5 ml of fasting blood sample was collected from the forearm between 8 and 10 am in all women and centrifuged at 3,000 rpm, and attained sera were kept at −80 °C. The total oxidant status (TOS) in the plasma was measured using a novel automated colorimetric measurement method developed by Erel. According to this method, oxidants present in the sample oxidize the ferrousion-o-dianisidine complex to ferric ion. The results are expressed in terms of micromole hydrogen peroxide equivalent per liter (μmol H2O2 Eq/L) [10]. The total antioxidant status (TAS) in the plasma was measured using a novel automated colorimetric measurement method developed by Erel [9]. According to this method, the hydroxyl radical, which is produced by the Fenton reaction, reacts with the colorless substrate o-dianisidine to produce the bright yellowish-brown dianisyl radical. The assay results are expressed as mmol Trolox Eq/L. TAS and TOS levels in 4 phases of treatment cycle (before OPU, after OPU, before ET, after ET) between clinically pregnant and clinically non-pregnant patients were compared. Critical cut-off values of significantly different TAS and TOS levels for clinical pregnancy were calculated. The oxidative stress indexes (OSI: TOS/TAS) for the evaluation of systemic oxidative stress and antioxidant response in ovarian stimulation and intracytoplasmic sperm injection (ICSI) outcomes were also calculated and critical cut-off value for significant OSIes were found.

This study was statistically analyzed using SPSS IBM 20 and Medcalc 11.3. For all variables, the Shapiro Wilk test was used to assess normality. For normally distributed variables, paired-sample t-tests and independent-sample t-tests were applied, and the mean ± standard deviation values were presented. Wilcoxon’s signed rank test and the Mann–Whitney U test were applied for non-normally distributed variables, and median (25 %–75 %) percentiles were presented. Critical cut-off values of significantly different TAS and TOS levels, OSIes for clinical pregnancy were evaluated with ROC curve analysis. According to power analysis calculations, the power of the study was >80 % for measurements of TAS before and after ET and TOS after oocyte retrieval. The sample size must be at least 14 in each group to obtain 80 % power for TOS measurements before ET and at least 24 for TOS measurements after ET. A power analysis was performed for variables that were evaluated with parametric statistical tests.

Results

The cycle outcome and clinical data of 70 couples with primary infertility are summarized in Table 1. No significant difference was noted between couples who had positive clinical pregnancy and those who did not in terms of the woman’s age, duration of infertility, day 3 FSH-LH-estradiol levels, day 3 AFC, number of retrieved oocytes, number of day 3 grade I+II embryos or number of transferred embryos.

Table 1

The demographic characteristics of the study population

	Clinically pregnant (n = 22)	Clinically non-pregnant (n = 48)	P value
Female age (years)	31.5 ± 3.9	32 ± 3.2	NS
BMI (kg/m2)	23.4 ± 2.9	24.2 ± 2.1	NS
Duration of infertility (years)	3.1 ± 1.9	2.9 ± 2.0	NS
Basal FSH (mIU/ml)	7.1 ± 2.1	8.3 ± 1.6	NS
Basal LH (mIU/ml)	5.1 ± 1.2	4.7 ± 1.4	NS
Basal estradiol (pg/ml)	37 ± 7	36 ± 9	NS
Basal antral follicle count	9 ± 2.1	10 ± 1.9	NS
Number of retrieved oocytes	15 ± 4.1	14 ± 4.9	NS
Fertilization rate (%)	85 ± 6.1	79 ± 4.9	NS
Number of day-3 grade I+II embryos	7 ± 2.3	6 ± 3.0	NS
Number of transferred embryos	1 ± 0	1 ± 0	NS

Data are represented with the form of the Mean ± Standard Deviation (SD)

BMI Body Mass Index; FSH Follicle Stimulating Hormone; LH Luteinizing Hormone; NS Non-significant

P-value <0.05 was considered statistically significant

Measurements obtained prior to OPU in patients with and without clinical pregnancy revealed median TOS levels of 1.66 μmol H2O2 Eq/L and 1.60 μmol H2O2 Eq/L (P = 0.092), respectively, and median TAS levels of 1.70 mmol Trolox Eq/L and 1.55 mmol Trolox Eq/L (P = 0.035), respectively. Measurements obtained after OPU in patients with and without clinical pregnancy revealed mean TOS levels of 1.63 μmol H2O2 Eq/L and 1.58 μmol H2O2 Eq/L (P = 0.013), respectively, and median TAS levels of 1.66 mmol Trolox Eq/L and 1.58 mmol Trolox Eq/L (P = 0.010), respectively (Table 2).

Table 2

TAS and TOS levels before-after oocyte collection, before-after embryo transfer in clinically pregnant and non-pregnant women

	Clinically pregnant (n = 22)	Clinically non-pregnant (n = 48)	P value
TAS before OPU	1,70(1,55–1,70)	1,55(1,54–1,59)	0.035
TAS after OPU	1,66(1,58–1,68)	1,58(1,57–1,62)	0,010
TOS before OPU	1,66(1,58–1,68)	1,60(1,54–1,62)	0.092
TOS after OPU	1,63±,057	1,58±,050	0,013
TAS before ET	1,65±,072	1,59±,054	0,022
TAS after ET	1,68±,059	1,62±,052	0.010
TOS before ET	1,65±,063	1,58±,062	0.014
TOS after ET	1,62±,061	1,57±,066	0.065

For normally distributed variables Mean ± Standard Deviation (SD) values were given, for non-normally distributed variables median (25 %–75 %) percentiles were given

Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum total oxidant (TOS) in μmol H2O2 Eq/L unit

OPU oocyte pick-up, ET embryo transfer

P-value <0.05 was considered statistically significant

Prior to ET in patients with and without clinical pregnancy, the mean TOS levels were 1.65 μmol H2O2 Eq/L and 1.58 μmol H2O2 Eq/L (P = 0.014), respectively, and the mean TAS levels were 1.65 mmol Trolox Eq/L and 1.59 mmol Trolox Eq/L (P = 0.022), respectively. Measurements obtained after ET in patients with and without clinical pregnancy revealed mean TOS levels of 1.62 μmol H2O2 Eq/L and 1.57 μmol H2O2 Eq/L (P = 0.065), respectively, and mean TAS levels of 1.68 mmol Trolox Eq/L and 1.62 mmol Trolox Eq/L (P = 0.010), respectively (Table 2). The TAS levels in patients with clinical pregnancy were significantly higher prior to and after OPU and ET (Fig. 1, Table 2). In addition, TOS measurements after OPU and prior to ET were significantly higher in patients who had clinical pregnancy (Table 2). Comparison of TOS and TAS levels in different phases of COH cycles in clinically pregnant and non-pregnant patients were demonstrated in Tables 3 and 4.

Fig. 1

Serum total antioxidant status (TAS) levels in clinically pregnant and non-pregnant women around oocyte collection and embryo transfer

Table 3

Comparison of TOS and TAS levels in different phases during COH cycles in clinically pregnant patients

Phases of cycle
	TOS levels	P value
Before OPU-after OPU	1,61±,061–1,63±,057	0.014
Before ET-after ET	1,65±,063–1,62±,061	0,003
Before OPU-after ET	1,61±,061–1,62±,061	0.528
	TAS levels	P value
Before OPU-after OPU	1,64±,075–1,64±,049	0,831
Before ET-after ET	1,68(1,57–1,72)–1,71(1,63–1,74)	0.007
Before OPU-after ET	1,64±,075–1,68±,059	0.003

For normally distributed variables Mean ± Standard Deviation (SD) values were given, for non-normally distributed variables median (25 %–75 %) percentiles were given

Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum total oxidant (TOS) in μmol H2O2 Eq/L unit

OPU oocyte pick-up, ET embryo transfer

P-value <0.05 was considered statistically significant

Table 4

Comparison of TOS and TAS levels in different phases during COH cycles of clinically non-pregnant patients

TOS levels		P value
Before OPU-after OPU	1,57±,046–1,58±,050	0.778
Before ET-after ET	1,60(1,54–1,62)–1,58(1,52–1,60)	0,020
Before OPU-after ET	1,57±,046–1,57±,066	0.552
TAS levels		P value
Before OPU-after OPU	1,57±,053–1,59±,043	0,017
Before ET-after ET	1,59±,054–1,62±,052	<0.001
Before OPU-after ET	1,57±,053–1,62±,052	<0.001

For normally distributed variables Mean ± Standard Deviation (SD) values were given, for non-normally distributed variables median (25 %–75 %) percentiles were given

Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum total oxidant (TOS) in μmol H2O2 Eq/L unit

OPU oocyte pick-up, ET embryo transfer

P-value <0.05 was considered statistically significant

According to OSI calculations it was found that; only the pre-OPU OSI was significantly lower in clinically pregnant patients (0.970) compared with non-pregnant ones (1.006) (P = 0.008) (Table 5). Critical cut-off values of significantly different TAS and TOS levels, OSIes for clinical pregnancy were determined. They were <0.98 mmol Trolox Eq/μmol H2O2 Eq with AUC = 0.806 (95%CI, 0.617–0.928) and p = 0.001 for OSI before OPU; >1.6 mmol Trolox Eq/L with AUC = 0.747 (95%CI, 0.552–0.889) and p = 0.032 for TAS before OPU; >1.65 mmol Trolox Eq/L with AUC = 0.800 (95%CI, 0.611–0.924) and p < 0.001 for TAS after OPU; >1.64 mmol Trolox Eq/L with AUC = 0.722 (95%CI, 0.526–0.871) and p = 0.074 for TAS before ET; >1.67 mmol Trolox Eq/L with AUC = 0.786 (95%CI, 0.595–0.916) and p = 0.003 for TAS after ET; >1.64 μmol H2O2 Eq/L with AUC = 0.758 (95%CI, 0.564–0.897) and p = 0.016 for TOS after OPU; >1.64 μmol H2O2 Eq/L with AUC = 0.761 (95%CI, 0.567–0.899) and p = 0.017 for TOS before ET. ROC analysis of significantly different seven measurements were shown in Figs. 2 and 3.

Table 5

OSI in different phases during COH cycles in clinically pregnant and non-pregnant women

OSI	Clinically pregnant (n = 22)	Clinically non-pregnant (n = 48)	P value
Before OPU	0,970(0,976–1,000)	1,006(0,987–1,012)	0.008
After OPU	1,000(0,984–1,008)	0,990(0,976–1,009)	0,555
Before ET	0,994(0,994–1,003)	0,997(0,987–1,006)	0.688
After ET	0,965(0,947–0,971)	0,963(0,950–0,979)	0,832

Median (25 %–75 %) percentiles were given

Differences were evaluated with Mann–Whitney U test

OPU oocyte pick-up, ET embryo transfer, OSI oxidative stress index

P-value <0.05 was considered statistically significant

Fig. 2

ROC curve analysis for OSI before OPU. Sensitivity and specificity rates were given for pre-OPU OSI value which was significant for predicting clinical pregnancy and AUC was 0.806 (95%CI, 0.617–0.928) with p = 0.001. Pre-OPU OSI as in mmol Trolox Eq/μmol H2O2 Eq. (OPU; oocyte pick-up, OSI; oxidative stress index)

Fig. 3

ROC Curve analysis for measured variables that were significant for predicting clinical pregnancy. Significant critical cut-off values of TAS and TOS in different phases of COH cycle were given with sensitivity and specificity rates; a TAS prior to OPU, b TAS after OPU, c TAS before ET, d TAS after ET, e TOS after OUP, f TOS before ET. Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum total oxidant (TOS) in μmol H2O2 Eq/L unit. OPU; oocyte pick-up, ET; embryo transfer

Discussion

Our study showed that the blood TAS level during OPU (pre and post) and ET (pre and post), most likely the most important phases in the ART-ICSI cycle, has a predictive value for clinical pregnancy. All measurements obtained before and after these important stages showed that TAS levels were significantly higher in patients who developed clinical pregnancy; the TAS levels before OPU were 1.70 mmol Trolox Eq/L vs. 1.55 mmol Trolox Eq/L (P = 0.035), respectively, and 1.66 mmol Trolox Eq/L vs. 1.58 mmol Trolox Eq/L after OPU (P = 0.010), respectively. Before ET, the TAS levels were 1.65 mmol Trolox Eq/L vs. 1.59 mmol Trolox Eq/L (P = 0.022) in patients with and without clinical pregnancy, respectively, and after ET, the TAS levels were 1.68 mmol Trolox Eq/L and 1.62 mmol Trolox Eq/L (P = 0.010), respectively.

Although oxidative stress has an impact on male infertility, the number of studies on female infertility has increased recently [2, 3]. In an animal model study, Duleba et al. [8] showed that oxidative stress negatively affected the development of theca-interstitial cells. In contrast, oxidants have been shown to play a role in folliculogenesis, follicular maturation and ovulation [11, 19, 20]. Thus, it is likely that oxidative stress may affect oocyte development and the development of embryos [2]. In a clinical study, Das et al. [7] found that ROS levels in follicular fluid measured by the chemiluminescence method have an impact on the development and quality of embryos; additionally, the oocyte fertilization capacity diminished as ROS increased in the follicular fluid of 78 couples who were admitted to IVF treatment because of tubal infertility.

Oyawoye et al. [14] measured the basal total antioxidant capacity (TAC) and decline of TAC in the follicular aspirates of 63 couples and 303 follicle aspirations with a ferric-reducing antioxidant power (FRAP) assay. Although it was interesting to note that the decline in TAC was lower when the oocytes were fertilized and higher in association with embryo viability, ROS may have different effects at different stages of embryo development. In our study, in addition to the high levels of TAS at all measured times in the clinically pregnant group, TOS levels after OPU and prior to ET were also higher in patients with clinical pregnancy. But according to OSI values only lower OSI before OPU was significant for predicting clinical pregnancy. Moreover the highest AUC value, from the seven different significant measurements [1) pre-OPU OSI, 2) TAS prior to OPU, 3) TAS after OPU, 4) TAS before ET, 5) TAS after ET, 6) TOS after OUP, 7) TOS before ET], was 0.806 and related to pre-OPU OSI (Figs. 2 and 3). So, high levels of TOS at certain measurement times support the idea that elevated antioxidant levels alone are not sufficient for the development of clinical pregnancy; ROS may affect different phases of embryo development, and the balance between oxidants and antioxidants may be as important as the antioxidant concentration.

In most of the studies on the role of ROS and antioxidants in ART treatment instead of clinical pregnancy, oocyte retrieval and/or fertilization and/or embryo development were considered as endpoints. Moreover, although isolated oxidative stress markers were used to determine ROS levels in some studies, total TOS measurement was performed in others [7, 11, 14]. Regarding TAS levels, isolated antioxidants were measured in some studies, while total TAS was measured in others [7, 14, 18]. Additionally, different methods were used for the measurements. These factors make it difficult to comment on how TAS and TOS affect clinical pregnancies because different substances were measured from different sites using different methods. In this study, we performed our measurements using the Erel method, which can determine the total antioxidant level to determine the TAS level [9]. We also measured TOS levels with the Erel method, which detects total oxidant levels instead of different oxidants [10]. In addition, measurements were obtained in female serum. To achieve clinical pregnancy, oocyte retrieval, fertilization and embryo development and endometrial implantation following ET are crucial. For this reason, we measured TAS and TOS levels only in the female serum, assuming that antioxidants and oxidants would be effective in all of the phases (oocyte development, embryo development and implantation). A unique facet of this study is that we determined the effect of serum TAS and TOS levels on predicting clinical pregnancy, which not only reflects folliculogenesis and embryogenesis but also systemic effects that may influence implantation.

In contrast, Oyawoye et al. [15] showed that the total antioxidant capacity depends on the etiology of infertility. The follicular total antioxidant capacity was higher in patients with unexplained infertility and tubal factor infertility, while in patients with polycystic ovaries, an increase in total antioxidant capacity was related to fertilization incompetence. As Agarwal et al. [3] noted an imbalance between pro-oxidants and antioxidants can cause pathologies such as; endometriosis, PCOS, unexplained infertility and obstetric complications such as; abortion and preeclampsia. Therefore to improve the homogeneity of our study population, only infertile couples with male factor infertility were included in this study and most probably this is one of the most important limitations of our study. There is no suspicion about the effect of OS on male fertility, but our aim was to evaluate the effect of female OS on obtaining clinical pregnancy which develops after successful folliculogenesis, fertilization, embryogenesis and implantation. Studying with only male factor infertility couples is one of the most suitable designs that could show us the effect of female OS on clinical pregnancy. Additionally we also studied couples only with sperm can be obtained from ejaculation, so we totally excluded couples who had surgical sperm extraction or aspiration indication due to azoospermia. New studies including study groups of patient’s exclusively with only one of the female infertility or male infertility etiology will improve our knowledge about this topic. Briefly; in an effort to induce the impact of oxidative stress induced by infertility etiology on our results minimal, we studied with couples who had only male factor infertility.

On the other hand, a study that was conducted with salivary stress biomarkers (cortisol and α-amylase) showed that stress in the fertile window decreased the probability of conception [13]. The results of this study suggest that in couples that have similar infertility etiology, smoking status and age, high levels of serum TAS levels prior to and after OPU and ET increase the chance of pregnancy. Therefore, the amount of stress and the resultant imbalance between pro-oxidants and antioxidants in women during ART cycles has an impact on the occurrence of spontaneous pregnancy. In our study, we did not measure stress biomarkers, but due to the homogeneity of our study population, we believe that one of the most probable factors that affected the pregnancy rates and TAS/TOS levels is stress. Due to stress-related imbalances in oxidants and antioxidants, clinical pregnancy development was affected.

Currently, the trend is multivitamin and mineral supplementation in infertile patients in the aim of strengthening the antioxidant defense mechanism [16]. However, it seems obvious that we must strike a balance between antioxidants and oxidants instead of supplying infertile patients with antioxidant medications. Additionally, we must also attempt to decrease the stress of infertile patients.

One of the other limitations of the present study is that it is a prospective cohort study and not a randomized controlled trial; therefore, there may have been confounding variables influencing the results. However, we were able to show that the two study groups were comparable with respect to several parameters, including age, body mass index, and basal serum FSH levels, and therefore, the possibility of selection bias appear minimal. In contrast, none of the tests used for measuring TAS and/or TOS were demonstrated as the gold standard, and there is no consensus regarding which antioxidants or oxidants must be measured. However, we used novel Erel methods for both of the measurements.

In conclusion, in ART treatment cycles entirely indicated for male factor infertility, women with higher serum TAS levels in four major phases of COH cycles (pre-OPU, post-OPU, pre-ET, post-ET) and with higher TOS levels pre-OPU and post-ET have an increased probability of clinical pregnancy. Additionally; OSI before OPU was one of the most important determinants for clinical pregnancy so the oxidant and antioxidant balance is as important as the antioxidant concentration alone.